Ultragenyx Pharmaceutical Inc. (RARE) Stock Grade

About Ultragenyx Pharmaceutical Inc.'s fundamentals

Ultragenyx Pharmaceutical is a $2.3 billion biotechnology company experiencing strong revenue growth of 20.1% year-over-year, indicating expanding business activity. However, the company operates at a significant loss, with a net margin of -85.4%, meaning it spends substantially more than it generates in revenue. The company does not pay a dividend, which is typical for loss-making biotech firms that reinvest capital into research and development. Given the absence of profitability, traditional valuation metrics like the P/E ratio are not applicable.